Effect of Euphorbia microsciadia Boiss Extract on Cell Proliferation and Cytokine Expression in Breast Cancer Cell Line MDA-MB-231

Document Type : Original Article


1 Assistant Professor of Thalassemia and Hemoglobinopathy Research Center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Assistant Professor of Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

3 Assistant Professor of Pediatric Hematology and Oncology Department of Pediatrics, School of Medicine Shahid Baghaei the 2nd Hospital Ahvaz Jundishapur University of Medical sciences


Background and aim: Euphorbia microsciadia Boiss is a plant used in traditional medicine for cancer treatment in many countries. The purpose of this study was to determine the effect of E. microsciadia extract on the elimination of tumor cells and the expression of cytokines in the breast cancer cell line MDA-MB-231.
Materials and methods: The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, penicillin and streptomycin. The effect of the extract on the viability of MDA-MB-231 cells was evaluated by MTT assay. To evaluate the expression level of the mRNA after MDA-MB-231 cell line treatment with the plant extract, the RNA was extracted to cDNA synthesis. The mRNA expression level was measured in the samples by TaqMan real-time PCR technique.
Results: After 24 and 48 h, the IC50 values for the E. microsciadia extract were 278.30 and 238.20μg/ml, respectively. The extract exhibited anti-proliferative effects on the MDA-MB-231 cell line in a dose- and time-dependent manner. The expression levels of INF-γ IL-8 and IL-1β were significantly increased 24 and 48 hours after the extract treatment. The expression levels of TGF-β1, IL-6, IL-10 and IL-17A were increased after 24 h of treatment and decreased after 48 h of treatment.
Conclusion: The E. microsciadia extract may be used as a tool to manipulate the expression of cytokine genes and ultimately control cell growth and proliferation, which is essential for molecular and cellular studies in the cancer therapy.


1-Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313-7.
2-Naghavi M, Marczak LB, Kutz M, Shackelford KA, Arora M, Miller-Petrie M, et al. Global Mortality From Firearms,1990-2016. Jama. 2018;320(8):792-814.
3-Jarvandi S, Montazeri A, Harirchi I, Kazemnejad A. Beliefs and behaviours of Iranian teachers toward early detection of breast cancer and breast self-examination. Public Health. 2002;116(4):245-9.
4-Asadi-Samani M, Kooti W, Aslani E, Shirzad H. A Systematic Review of Iran's Medicinal Plants With Anticancer Effects. J Evid Based Complementary Altern Med. 2016;21(2):143-53.
5-Global battle against cancer won't be won with treatment alone--effective prevention measures urgently needed to prevent cancer crisis. Cent Eur J Public Health. 2014;22(1):23, 8.
6-Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3-15.
7-Imamura T, Hikita A, Inoue Y. The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis. Breast Cancer. 2012;19(2):118-24.
8-Bierie B, Moses HL. Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine & growth factor reviews. 2010;21(1):49-59.
9-Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
10-Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1826-30:(12)75;1997.
11-Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast cancer research and treatment. 2012;133(1):11-21.
12-Yeh TC, Huang TT, Yeh TS, Chen YR, Hsu KW, Yin PH, et al. miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells. PLoS One. 2016;11(12):e0168171.
13-Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693-706.
14-Hong DS, Angelo LS, Kurzrock R. Interleukin‐6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110(9):1911-28.
15-Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer. 2012;20(4):831-9.
16-Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004;23(36):6105-14.
17-Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang S-K. IL-17 cytokine family. Journal of Allergy and Clinical Immunology. 2004;114(6):1265-73.
18-Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K. Interleukin-8 and interleukin-17 for cancer. Cancer Invest. 2014;32(5):197-205.
19-Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407(2):348-54.
20-Sharma N, Samarakoon KW, Gyawali R, Park YH, Lee SJ, Oh SJ, et al. Evaluation of the antioxidant, anti-inflammatory, and anticancer activities of Euphorbia hirta ethanolic extract. Molecules. 2014;19(9):14567-81.
21-Kwan YP, Saito T, Ibrahim D, Al-Hassan FM, Ein Oon C, Chen Y, et al. Evaluation of the cytotoxicity, cell-cycle arrest, and apoptotic induction by Euphorbia hirta in MCF-7 breast cancer cells. Pharm Biol. 2016;54(7):1223-36.
22-Choene M, Motadi L. [Validation of the Antiproliferative Effects of Euphorbia tirucalli Extracts in Breast Cancer Cell Lines]. Mol Biol (Mosk). 2016;50(1):115-27.
23-Zare S, Ghaedi M, Miri R, Heiling S, Asadollahi M, I TB, et al. Phytochemical Investigation on Euphorbia macrostegia (Persian wood spurge). Iran J Pharm Res. 2015;14(1):243-9.